Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Geigy, formally known as J. R. Geigy Ltd, was a foundational Swiss pharmaceutical and chemical company headquartered in Basel. Established in 1758, the firm evolved from a chemical and dye manufacturer into a global leader in the pharmaceutical industry, responsible for discovering several landmark therapies. Notable achievements include the development of the first tricyclic antidepressant, Tofranil (imipramine), and the widely used anticonvulsant Tegretol (carbamazepine). The company's research also led to the discovery of the insecticidal properties of DDT, which earned researcher Paul Müller the Nobel Prize in 1948. In 1970, Geigy merged with Ciba to form Ciba-Geigy, which subsequently merged with Sandoz in 1996 to create Novartis. Today, Geigy's scientific legacy and product portfolio remain integral components of Novartis's global operations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Geigy.